Purpose Gefitinib has shown high response rate and improved progression-free survival
(PFS) in never-smokers with lung adenocarcinoma (NSLAs). We compared efficacy of …

Purpose Patients with natural killer T (NK/T)-cell lymphomas have poor survival outcome,
and for this condition there is no optimal therapy. The purpose of this study was to design a …

Background Based on the encouraging activity and manageable safety profile observed in a
phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of …

Purpose To explore a more effective treatment for newly diagnosed stage IV, relapsed, or
refractory extranodal natural killer/T-cell lymphoma, nasal type (ENKL), we conducted a …

PURPOSE Ibrutinib has shown activity in non–germinal center B-cell diffuse large B-cell
lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus …

Background. With the introduction of cisplatincontaining regimens in the treatment of
advanced gastric cancer, promising clinical results have been reported. A 61.5% response …

Beta-2 microglobulin is synthesized in all nucleated cells and forms the light chain subunit of
the major histocompatibility complex class I antigen. Despite its potential role as a …

PURPOSE: On the basis of the benefits of frontline radiation in early-stage, extranodal,
natural killer (NK)/T-cell lymphoma (ENKTL), we conducted a phase II trial of concurrent …

Background The clinical outcome of extranodal natural killer T-cell lymphoma (ENKTL) has
improved substantially as a result of new treatment strategies with non-anthracycline-based …

Considering whole-brain radiotherapy (WBRT) for asymptomatic brain metastases can
reduce performance status and delay systemic treatment, primary chemotherapy can be a …